| INTRODUCTION
Cerebral malaria (CM) is a leading cause of mortality from Plasmodium falciparum infection with a mortality rate of 13-15%. [1] [2] [3] CM is also an important cause of short 4 -and long-term 5 neurocognitive impairment in African children. Tumour necrosis factor-alpha (TNF-α) is considered an important contributor to CM pathogenesis due to its role in promoting endothelial activation, which can further increase binding of infected erythrocytes (IE) to host endothelium, 6, 7 an important hallmark of CM.
In mouse models of malaria, TNF-α has been shown to reduce parasitemia and protect against the early stages of infection [8] [9] [10] [11] but has also been associated with disease severity when elevated at later stages. 9 TNF-α has also been shown to be essential in the pathogenesis of experimental cerebral malaria. 12, 13 This dual effect of TNF-α is thought to occur during human infections as well, as lower systemic TNF-α levels are seen at enrolment in patients with uncomplicated or mild malaria but higher levels are consistently detected in patients with severe malaria. [14] [15] [16] [17] [18] In humans, twofold to tenfold elevated systemic TNF-α levels have been associated with mortality in children with severe malaria 17, 19 and in children with CM specifically 16 in some studies, but not in others. 14 High plasma levels of TNF-α have also been associated with hyperparasitemia and hypoglycaemia, 16, 19 deeper coma 20 and endothelial activation 17 in severe malaria. In addition, TNF-α polymorphisms associated with high TNF-α expression were more prevalent in patients with CM and fatal CM. 21, 22 However, the use of antibodies against TNF-α did not reduce mortality and was associated with increased risk of neurologic deficits in children with CM, 23 suggesting that more work is needed to understand the role of this cytokine not only systemically but also locally in the central nervous system (CNS).
In the CNS, TNF-α production by microglia and astrocytes has been associated with fatal murine cerebral malaria. 24 The data from human studies of CNS TNF-α in CM patients are more limited, but also generally suggest a role for CNS TNF-α in CM: two studies have documented elevated cerebrospinal fluid (CSF) TNF-α levels in CM patients 20, 25 (another did not), 19 and autopsy studies of individuals who died of CM have shown TNF-α expression in the brain parenchyma. [26] [27] [28] Our group has previously shown that high levels of TNF-α at enrolment in the CSF but not plasma were associated with neurologic deficits and impaired attention and working memory postdischarge in children five years and older 25 suggesting a role for local TNF-α in the neurologic outcomes of CM. Whether these findings would be more severe in the developing brains of children <5 years old is not known.
To better assess the role of systemic and CNS TNF-α in children with CM across the typical age spectrum in which CM is seen in Africa,
we investigated how plasma and CSF TNF-α levels in Ugandan children 18 months to 12 years of age correlated with mortality, coma duration and acute and long-term neurologic and cognitive deficits and assessed whether plasma and CSF TNF-α levels differed according to the presence of malaria retinopathy.
| MATERIALS AND METHODS

| Study design
This prospective cohort study of the effects of severe malaria on neu- Children with CM were managed according to the Ugandan Ministry of Health treatment guidelines current at the time of the study. These included intravenous quinine treatment followed by oral quinine for severe malaria while admitted and artemisinin combination therapy for outpatient follow-up therapy.
Eligible CC were 18 months to 12 years of age, currently healthy, and were recruited from the household or neighbourhood of children with severe malaria. CC were recruited to be within the same age range as the children with severe malaria, using the age distribution from the first 45 children enrolled with severe malaria, but were not matched to specific children with severe malaria. Exclusion criteria for all children included the following: (i) known chronic illness requiring medical care; (ii) known developmental delay; or (iii) prior history of coma, head trauma, hospitalization for malnutrition or cerebral palsy.
Additional exclusion criteria for CC included the following: (i) illness requiring medical care within the previous 4 weeks or (ii) major medical or neurologic abnormalities on screening physical examination.
HIV-1 testing was performed if the parents or guardians of the child agreed to have this testing done. Three immunochromatographic tests (Determine, STAT-PAK and Uni-Gold) were used, and a final diagnosis of HIV infection was made based on the Uganda National HIV testing algorithm.
The study was reviewed and approved by the institutional review boards for human studies at the Makerere University School of
Medicine and the University of Minnesota. Written informed consent was obtained from parents or guardians of study participants.
| Malarial retinopathy diagnosis
Children were assessed for malarial retinopathy by means of indirect and direct ophthalmoscopy as previously described. 29 Ophthalmologic 
| Neurologic and cognitive assessment and follow-up
A neurologic deficit at discharge was defined as the presence of motor deficits, ataxia, movement disorder, behaviour or speech or visual disorders, in a child with no known prior deficits. Of the 79 children with CM that were discharged with neurologic deficits, 62 improved during the 6-month post-discharge, 11 had the neurologic deficits that persisted at the 6-month follow-up assessment, and six of those children did not return for the follow-up.
Children had cognitive assessment a week after discharge (or at enrolment for CC) and then at 6 and 12 months after enrolment. For children younger than 5 years old, the Mullen Scales of Early Learning 30 were used to measure cognitive ability. Scores from fine motor, visual reception, receptive language and expressive language scales were summed to give the early learning composite score, a measure of overall cognitive ability. Attention was assessed using the Early Childhood
Vigilance Test (ECVT), 31 in which a child was required to focus his/her gaze on cartoons screened on a computer for about 7 minutes. The measure of attention is the percent time the child spent gazing at the screen. In children 5 years and older, the Kaufman Assessment Battery for Children (second edition) was used to measure overall cognitive ability. 32 Lauria's model was used to obtain a composite score including sequential processing, simultaneous processing, learning ability and planning ability. Attention in these children was assessed using the Test of Variables of Attention (TOVA) 33 to measure attention and impulse control in four main areas: response time variability, response time, impulse control (commission errors) and inattention (omission errors). Neuropsychology testers were blinded to the study groups.
| TNF-α, endothelial activation marker and parasite biomass testing
In the prospective cohort study, cytokine testing was performed on admission plasma and CSF samples. CSF samples were obtained as part of standard work-up for children with CM in whom a lumbar puncture was not contraindicated. 0.5-2 mL of the CSF sample was stored at −80°C for later study testing. As there was no noninfected population in Mulago Hospital from which CSF could ethically be obtained, CSF control samples were obtained from asymptomatic North
American children successfully treated for prior leukaemia who had CSF obtained after treatment to rule out return of malignancy (ruled out in all). Plasma samples from these North American children were not available.
Plasma and CSF levels of TNF-α were measured by magnetic cyometric bead assay (EMD-Millipore, Billerica, MA, USA) according to manufacturer's instructions with a BioPlex-200 system (BioRad, Hercules, CA, USA). Peripheral blood smears were assessed for
Plasmodium species by microscopy with Giemsa staining using standard protocols. PfHRP-2 quantification was performed using the Malaria Ag CELISA (Cellabs, Brookvale, Australia). Total, circulating and sequestered parasite biomass were calculated as previously described. 
| Statistical analysis
Demographic characteristics were compared using t tests for continuous measures and Pearson's chi-square test for categorical variables. Plasma and CSF TNF-α levels, endothelial activation markers, coma duration and number of seizures had skewed distributions, so for these variables, Wilcoxon rank-sum testing was used for comparisons between groups (e.g., children with vs without neurologic deficits), and Spearman's rank correlation (rho) was used for assessment of correlations with continuous variables. Age-adjusted z-scores for cognitive outcomes were created using the scores of the CC. 4, 5 For each outcome, the z-score was computed as (actual score minus average score for child's age)/SD, where "average score for child's age" and "SD" were computed by fitting a mixed linear model to data from all available visits for CC (allowing correlated errors for a child's multiple visits). Z-scores have average of 0 and SD 1 in the reference population (CC) over all time points.
| RESULTS
| Demographic characteristics of children with cerebral malaria and community children
A total of 268 children with cerebral malaria and 213 community controls (CC) were enrolled in this study. A total of 249 children with CM and 198 CC had sufficient plasma for TNF-α testing. Of the 249 children with CM who had plasma available for testing, 167 had sufficient CSF for TNF-α testing.
Children with CM and the CC were of similar age, but a higher proportion of children with CM were male ( Table 1) . By definition, parasite densities were higher in children with CM (Table 1) . HIV prevalence was low in our cohort of children with CM (2.2%), possibly reflecting the exclusion criterion of known chronic illness, and by definition, HIV infection was not present in the cohort of healthy community children. T A B L E 1 Demographic characteristics of children with cerebral malaria and healthy community control children
| Plasma and CSF TNF-α levels in children with CM do not correlate with age, sex, nutrition or HIV status
Plasma and CSF TNF-α levels were not associated with age (P>.11 for both), sex (P>.20 for both), nutritional status (weight for age z-score, P>.3 for both) or HIV status (P>.10 for both) in children with CM, and as a result, these factors were not adjusted for in the following analysis of TNF-α with acute and long-term outcomes in CM.
| Plasma TNF-α levels in children with CM correlate with parasite biomass and endothelial activation
Plasma TNF-α levels correlated strongly and positively with all markers of endothelial activation (P<.0005 for all, Table 2 ) except VWF.
Plasma TNF-α levels were also associated with increased PfHRP-2 levels, as well as total, circulating and sequestered parasite biomass (P<.0001 for all, Table 2 ).
3.4 | Plasma TNF-α levels are higher in children with CM than community children and correlate weakly with CSF TNF-α levels in children with CM Plasma TNF-α levels in children with CM were significantly higher than CC ( Figure 1A ) recruited from the same households or neighbourhoods of children with CM. Median levels of plasma and CSF TNF-α were similar between the two age groups in CM (plasma, n=194, 107 pg/ mL for <5 years, n=55, 83.2 pg/mL for ≥5 years, P=.07; CSF, n=136, F I G U R E 1 Plasma and cerebrospinal fluid (CSF) TNF-α levels are higher in children with cerebral malaria at enrolment compared to controls. 
| Plasma and CSF TNF-α levels in children with CM do not differ according to malaria retinopathy
The presence of malarial retinopathy at admission has been associated with brain sequestration post-mortem in cerebral malaria, 35 but it is unclear whether children with clinical CM and no retinopathy have a milder form of CM or an alternative cause of coma. We compared TNF-α levels in children with CM with vs without retinopathy. Plasma TNF-α levels did not differ significantly between retinopathy positive and retinopathy negative children with CM (P=.67, Figure 2A ). CSF TNF-α levels also did not differ significantly between RP and RN children with CM (P=.30, Figure 2B ).
| Plasma and CSF TNF-α levels in children with CM do not differ according to acute mortality
Plasma TNF-α levels did not differ significantly between children with CM who died vs those that survived (P=.28, Figure 3A ). CSF TNF-α levels also did not differ significantly between children with CM who died and those who survived (P=.59, Figure 3B ).
| Elevated CSF TNF-α levels are associated with prolonged coma during admission, neurologic deficits at discharge and 6-month follow-up and deficits in overall cognition at 12-month follow-up
Plasma TNF-α levels did not differ significantly between children with vs without neurologic deficits at discharge (P=.41, Figure 4A) and between children with CM with or without neurologic deficits at 6-month follow-up (P=.63, Figure 4A ). However, levels of TNF-α in the CSF were significantly higher in children with CM who were discharged with neurologic deficits (P=.04, Figure 4B ). CSF TNF-α levels at enrolment were also higher in children that had neurologic deficits at 6-month follow-up compared to those who did not (P=.05, Figure 4B ). Similarly, CSF TNF-α, but not plasma TNF-α, was positively associated with coma duration in children with CM (Table 3) . Neither plasma nor CSF TNF-α levels were associated with number of seizures during admission (Table 3) .
Plasma TNF-α levels were not associated with deficits in the areas of overall cognition and attention at 12-month follow-up in children <5 years or children ≥5 years of age (P>.59 for all, Table 4 ). In children ≥5 years of age, elevated CSF TNF-α levels were associated with lower z-score values for overall cognition but not attention at 12-month follow-up (Table 4 ). However, there was no association between CSF TNF-α levels and cognition or attention in children <5 years of age.
Overall cognition and attention scores at 12-month follow-up were not significantly different between children with CM who had HIV and neurocognitive testing (n=4) compared to those who did not have HIV (n=170 for overall cognition and n=173 for attention) (all P>.07).
| CSF TNF-α levels are higher in Ugandan children with CM than in currently healthy North American control children with prior neoplastic disease
To estimate whether CSF TNF-α levels were in the normal range in F I G U R E 4 Cerebrospinal fluid (CSF) TNF-α levels are higher in children with cerebral malaria who had neurologic deficits at discharge or 6-month follow-up. (A) Plasma (no deficits at discharge, n=138 and deficits at discharge, n=79; no deficits at 6-month follow-up, n=198 and deficits at 6-month follow-up, n=11) and (B) CSF TNF-α (no deficits at discharge, n=93 and deficits at discharge, n=63; no deficits at 6-month follow-up, n=141 and deficits at 6-month follow-up, n=10) at enrolment based on neurologic outcomes at discharge or 6-month follow-up (values on a logarithmic scale). The horizontal line represents median values. Two-sample Wilcoxon rank-sum (Mann-Whitney) test was used to compare median levels between groups 
No deficits Deficits No deficits Deficits
Plasma TNF-α (pg/mL) CSF TNF-α (pg/mL) T A B L E 3 Association of plasma and cerebrospinal fluid (CSF) TNF-α levels with number of seizures and duration of coma during hospitalization CM had significantly higher CSF levels of TNF-α as compared to control North American children with prior neoplastic disease (P<.0001 Figure 1B ). Unfortunately, plasma samples from the North American children were not available, so we could not assess the association of plasma with CSF TNF-α in this group. However, considering that most CSF TNF-α levels were at the limit of detection ( Figure 1B ) and that the North American children were healthy at the time of sample collection, we expect plasma levels of TNF-α in the North American children would be <50 pg/mL, as in studies of other healthy children from high-income countries, 36, 37 and similar to our study's Ugandan CC controls (18-42 pg/mL).
| DISCUSSION
In the present study, we show that CSF but not plasma TNF-α correlates with key clinical outcomes in children with CM, including coma duration, acute and long-term neurologic deficits and long-term cognitive outcomes. The study findings demonstrate the importance of CNS TNF-α in the neurologic outcomes in children with CM and suggest that CNS TNF-α and factors, such as sequestered parasite biomass, that appear to affect CNS TNF-α production, may be good targets for adjunctive therapy to reduce neurologic morbidity in CM.
Plasma TNF-α levels were fourfold higher in children with CM as compared to healthy community controls and correlated with elevated levels of endothelial activation markers, parasite biomass and sequestered parasite biomass. It is difficult to know whether greater parasite burden led to greater TNF-α production from activated immune cells, or whether increased TNF-α led to greater endothelial activation and parasite binding, leading to increased sequestration and parasite biomass. Likely both phenomena are involved in the association. However, plasma TNF-α levels did not correlate with any clinical outcomes.
In contrast, CSF TNF-α levels correlated with acute (coma duration, neurologic deficits at discharge) and chronic (neurologic deficits at 6 months, worse neurocognitive scores at 12 months) CNS complications of CM. Elevated levels of TNF-α in the CNS can lead to tissue damage in cerebral ischaemic stroke, 38 spontaneous demyelination, 39 death of neurons and oligodendrocytes 40 and are involved in a number of other CNS disorders such as bacterial meningitis, 41 multiple sclerosis, 42 Parkinson's disease, 43 and murine 24 and human cerebral malaria. [26] [27] [28] Most human studies of CM that have looked at local TNF-α have done so in brain tissue. These studies allow for careful assessment of areas of the brain affected by TNF-α, but are limited in sample size and do not permit assessment of the role of CNS TNF-α in children who survive CM. This study and a prior study by our group 25 are, to our knowledge, the only studies to correlate CSF TNF-α levels with long-term sequelae. In both studies, plasma TNF-α levels were not correlated with any outcome. Together, the studies provide evidence that CNS TNF-α is associated with long-term neurologic and neurocognitive impairment in CM.
Parasite sequestration and systemic inflammation are thought to lead to BBB damage and leakage in CM, which could expose the brain parenchyma to plasma proteins and promote astrocyte and microglial activation. 44 In the present study, the albumin index and CSF-toplasma TNF-α ratio were strongly correlated, but the absolute values for TNF-α ratios were higher than the albumin index, suggesting that TNF-α found in the CSF may be partially produced in the CNS. Although we could not determine the cellular source of TNF-α in this study, the most likely sources are activated astrocytes and microglia. 40, 45, 46 It is unclear why CSF TNF-α levels were associated with impaired overall cognition only in children ≥5 years of age. It is possible that the effects of CNS TNF-α are better detected by the types of neurocognitive testing done in children ≥5 years of age as compared to those in done in children <5 years of age. Although the tests used are designed to test similar overall domains, the testing components and specific functions tested are different. Neural plasticity could allow better recovery from TNF-α-related CNS injury in younger children, but differences in cognitive scores between community children and children with CM overall were as large or larger in children <5 years and children ≥5 years of age (data not shown), so this explanation seems less likely as a reason for the differences. A recent study in a
Malawian paediatric cohort saw a high prevalence of HIV (15%) in children with CM. 47 CM children who were HIV positive were significantly older and had higher intravascular platelets and monocytes compared to children with CM but no HIV, 47 suggesting that HIV could be an additional complication in these older children with CM. Perhaps due to the exclusion of children with known chronic illness in the present study, the prevalence of HIV infection in children with CM in this cohort was much lower (2.2%). Levels of CSF TNF-α were not significantly different between children with CM who had HIV infection vs T A B L E 4 Association of plasma and cerebrospinal fluid (CSF) TNF-α levels with cognitive outcomes at 12-month follow-up .52 a TNF-α levels were log-transformed (log base 10).
those that did not, and neurocognitive outcomes also did not differ between children with CM who had HIV infection vs those who did not. Therefore, in the present study, HIV was not a major factor affecting neurocognitive outcomes. TNF-α in the CNS can have double functionality depending on the receptor it acts on and the stage of development. As an example, TNF-α by acting on TNFR2 promotes oligodendrocyte progenitor cell proliferation and remyelination but as oligodendroglia mature, TNF-α by acting on TNFR1 can reduce oligodendroglia maturation. 48, 49 How the local events during a CM episode affect TNFR1 and TNFR2 expressions and the expression of other cytokine and chemokines in the CNS needs further investigation.
Children in whom we did not have sufficient CSF to test for TNF-α were sicker than those for whom we were able to test CSF. This was not surprising, because the primary reason for not obtaining CSF was that the patient was too unstable to have a lumbar puncture or had a contraindication to lumbar puncture. As a result, the study findings likely underestimate the true associations of CNS TNF-α with mortality and acute and long-term complications of CM.
We did not see a significant difference in plasma TNF-α levels in CM children with vs without malarial retinopathy. These findings differ from a recent study in which higher neutrophil activation and higher plasma TNF-α levels were seen in retinopathy positive vs negative CM patients. 50 The reasons for this difference could be differences in the diagnosis of malarial retinopathy in the two sites or differences in the prevalence of TNF-α promoter polymorphisms, which were not identified in either study. Importantly, we also found that CSF TNF-α levels did not significantly differ between retinopathy positive and negative CM, suggesting that TNF-α is important in CM pathogenesis regardless of presence of retinopathy.
In conclusion, our study data show that plasma and CSF TNF-α levels are elevated in children with cerebral malaria and that elevated CSF TNF-α levels in children with CM are associated with prolonged coma, acute and long-term neurologic deficits, and long-term cognitive impairment. Our results emphasize the importance of studying both the peripheral and CNS immune responses because they do not always tell the same story. The data suggest that CNS TNF-α, as opposed to systemic TNF-α, is particularly important in neurologic outcomes in chil-
dren with CM and demonstrate the need for assessment of how age may alter the effects of risk factors for neurologic impairment. Further studies that aim to understand the role and regulation of CNS TNF-α in children with CM, with the goal of specifically targeting the CNS production and effects of TNF-α, could lead to adjunctive treatments that decrease neurologic morbidity in CM.
